Current nonclinical approaches for immune assessments of immuno-oncology biotherapeutics

Author:

Grimaldi Christine,Ibraghimov Alex,Kiessling Andrea,Rattel Benno,Ji Changhua,Fuller Claudette L.,Brennan Frank R.,Regenass-Lechner Franziska,Shenton Jacintha,Price Karen D.,Piché Marie-Soleil,Steeves Meredith A.,Prell Rodney,Dudal Sherri,Kronenberg Sven,Freebern Wendy,Blanset Diann

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference98 articles.

1. Oncology meets immunology: the cancer-immunity cycle;Chen;Immunity,2013

2. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo;Hipp;Leukemia,2017

3. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330;Krupka;Blood,2014

4. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens;Friedrich;Am Assoc Cancer Res,2012

5. Checkpoint Inhibitor-Induced Colitis: A New Type of Inflammatory Bowel Disease?;Bertha;Acg Case Reports J,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3